CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Diacine France SAS is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Diacine France SAS
27 Leanardo Da Vinci Street
Runners, 91090  France

Business Summary
Diacine France SAS is the holding company of Sebia SA, an in vitro diagnostics specialty company developing innovative diagnostics solutions for biologists and physicians in the fields of oncology, haemoglobin disorders and other metabolic disorders including diabetes.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
----Yes--

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
--Yes----

Industries
SIC Code Description
8741 Management services
6700 Holding and other investment offices

Subsidiaries
Business Name Address City State/Province Country
Sebia Parc Technologique Leonard de Vinci Lisses France
ORGENTEC Diagnostika GmbH Carl-Zeiss-Strasse 49-51 Mainz Germany

Business Names
Business Name
DIACINE FRANCE
Diacine France1
ORGENTEC Diagnostika GmbH
Sebia
Sebia SA


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024